What does Mannkind do and what are its main business segments?

What guidance did Mannkind's management provide for the next earnings period?

Did Mannkind beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Mannkind year over year?

What is the market's earnings forecast for Mannkind next quarter?

What is Mannkind's gross profit margin?

What factors drove the changes in Mannkind's revenue and profit?

What were the key takeaways from Mannkind’s earnings call?

- **Revenue Growth**: Q4 2025 revenue $112 million (+46% YoY), driven by FUROSCIX (+91% YoY) and Afrezza (+22% YoY)
- **Strategic Shift**: $200+ million annual run rate outside UT, up from $3.8 million in 2018
- **Pipeline Momentum**: MNKD-201 Phase II launch Q2 2026, Afrezza pediatric PDUFA May 29
- **Financial Strength**: $350 million guaranteed from UT DPI over 36 months, non-GAAP adj. net income $1.5 million Q4
- **Growth Catalysts**: FUROSCIX autoinjector July 2026, Afrezza pediatric launch H2 2026, MNKD-201 Phase Ib data H2 2026

**【CEO Opening Remarks】**
- Total Q4 2025 revenue: $112 million (+46% YoY), driven by FUROSCIX (+91% YoY) and Afrezza (+22% YoY). 
- Excluding Tyvaso DPI, MannKind now generates $200+ million annual run rate, up from $3.8 million in 2018.
- 2026 outlook: $450 million+ revenue run rate, with FUROSCIX targeting $110-120 million and Afrezza pediatric launch potential.
- Key initiatives: 
  1. FUROSCIX hospital pull-through via IDN protocols
  2. Doubling salesforce to 160 reps
  3. Marketing spend increase for autoinjector launch
  4. Afrezza pediatric PDUFA date May 29, 2026
  5. Furoscix Autoinjector PDUFA July 26, 2026

**【CFO Financial Commentary】**
- Q4 2025: GAAP net loss $15.9 million, non-GAAP adj. net income $1.5 million
- Full year 2025: GAAP net income $5.9 million, non-GAAP adj. net income $59.5 million
- Key revenue streams: 
  - FUROSCIX: $23.3 million (21% of Q4)
  - Afrezza: $22.3 million (20% of Q4)
  - UT DPI manufacturing: $26 million (23% of Q4)
- 2026 investments: $40 million in commercial growth (FUROSCIX/Afrezza)
- UT DPI supply agreement: $100 million in 2025, $50 million+ annually until 2031

**【CEO Pipeline Update】**
- MNKD-201 (Nintedanib DPI) Phase II global study launching Q2 2026
- IPF Phase Ib study enrolling, with top-line data H2 2026
- FTKP (Formulation Technology for Kinase Penetration) enabling deep lung delivery
- 2026 clinical milestones: 
  - Afrezza pediatric PDUFA May 29
  - Furoscix Autoinjector PDUFA July 26
  - MNKD-201 Phase Ib data H2

**【Q&A Highlights】**
- UT DPI supply agreement: $350 million guaranteed over 36 months
- MNKD-201 priority: "backbone of IPF therapy"
- FUROSCIX autoinjector COGS reduction potential
- Afrezza pediatric share potential 23-37% ($150M+ per 10% share)
- 2026 gross margin impact: $4 million in intangible amortization
- UT DPI royalty sensitivity: 9% net margin


MannKind Corporation(MNKD)-20260226-2025 Q4 Earnings call transcript

- **Revenue Record**: Q3 2025 revenue of $82 million, up 17% YoY, driven by Tyvaso DPI ($33M) and FUROSCIX ($19.3M). Year-to-date FUROSCIX revenue up 95% YoY.
- **Pipeline Breakthroughs**: Afrezza pediatric BLA under review; FUROSCIX auto-injector sNDA submitted. MNKD-701 (inhaled bumetanid) in preclinical development.
- **Strategic Expansion**: 80-person sales force expansion; 80-microgram Tyvaso cartridge reduces nebulizer breaths by 50%. CMS 2027 cardiorenal model alignment to reduce hospitalizations.
- **Financial Strength**: Non-GAAP net income up 45% YoY to $22.4M. $325M term loan supports scPharma integration and growth initiatives.
- **Growth Catalysts**: Q3 2025 dispensed FUROSCIX doses up 153% YoY. Auto-injector aims to simplify administration and reduce admission time.


**【CEO Summary Section】**
- **Record Revenue Growth**: Q3 2025 revenue reached $82 million, driven by Tyvaso DPI royalties ($33 million) and manufacturing-related revenue ($26 million). FUROSCIX contributed $19.3 million in Q3, with year-to-date revenue of $47.1 million, up 95% YoY.
- **Strategic Acquisitions**: Completed scPharmaceuticals acquisition, integrating their 80-person sales force to expand cardiorenal market presence. FUROSCIX auto-injector sNDA submitted, targeting Q3 2026 PDUFA date.
- **Pipeline Momentum**: Afrezza pediatric BLA under review with Q2 2026 PDUFA date. MNKD-701 (inhaled bumetanid) in preclinical development for fluid overload. Tyvaso DPI IPF bridging study planned post-UT TETON-2 data.
- **Commercial Expansion**: Expanded sales force to 80 reps, focusing on cardiologists and nephrologists. Launched 80-microgram cartridge for Tyvaso DPI, reducing nebulizer breaths from 15 to 1.

**【CFO Financial Commentary】**
- **Financial Performance**: Q3 non-GAAP net income $22.4 million (up 45% YoY), non-GAAP EPS $0.07 (up 17% YoY). Total revenue up 17% YoY, with commercial product sales (Afrezza, VGo) at 27% of total.
- **Balance Sheet**: $133 million used to fund acquisition, $325 million borrowed under 5-year term loan. Year-end 2025 pro forma commercial product sales would be 39% of total if FUROSCIX included.
- **Cost Management**: SG&A up 22% YoY due to scPharma integration and Afrezza pediatric launch prep. R&D up 9% YoY for ICoN-1 and MNKD-201 trials.

**【Q&A Highlights】**
- **FUROSCIX Growth**: Q3 dispensed doses up 153% YoY, with 27,000+ doses in Q3. Targeting CMS's 2027 cardiorenal risk model to reduce hospitalizations. Auto-injector aims to simplify administration and reduce admission time.
- **Competitive Landscape**: Competitors' pricing unclear, but focus on net patient cost and Medicare reimbursement. FUROSCIX's IV-like bioavailability differentiates it from generics.
- **Pipeline Updates**: MNKD-701 preclinical; MNKD-201 (nintedanib DPI) Phase II expected Q1 2026. Afrezza pediatric label expansion for postprandial control expected Q1 2026.
- **Integration Progress**: scPharma sales force fully integrated, with shared systems and processes. Key account managers added for hospital outreach. No disruption to existing operations.
- **Debt Strategy**: $36 million convertible note due March 2026 to be addressed. Focus on sustainable growth with new debt facility.


MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 6% YoY to $77M, driven by 22% YoY Afrezza prescription growth and 22% Tyvaso DPI royalty increase.
- **Strategic Capital**: $500M Blackstone deal provides non-dilutive funding for pipeline and commercial expansion.
- **Clinical Milestones**: 100-patient enrollment in inhaled clofazimine trial; Nintedanib DPI Phase II launch in 2025; pediatric Afrezza label submission Q4 2025.
- **Market Expansion**: Targeting 50% U.S. market coverage for Afrezza by 2026; exploring Japan NTM opportunity.

**【CEO Opening Remarks】**
- Emphasized strategic focus on creating shareholder value through five pillars: TETON 2 clinical trial readout, Afrezza growth, Blackstone capital partnership, inhaled clofazimine for NTM, and Nintedanib DPI Phase II for IPF.
- Q2 highlights: Record Tyvaso DPI royalties ($31M), 13% growth in Afrezza revenue, $201M cash balance, and 100-patient enrollment in inhaled clofazimine trial.
- Future catalysts include pediatric Afrezza label submission (Q4 2025), INFLO trial launch for Nintedanib DPI, and international expansion of Afrezza.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $77M (6% YoY growth), with $18M from Afrezza (13% YoY) and $31M from Tyvaso DPI (22% YoY growth).
- Blackstone deal provides $500M non-dilutive capital for commercial expansion, pipeline advancement, and business development.
- R&D expenses increased due to clinical trial enrollment, while SG&A rose with commercial infrastructure investments.

**【Q&A Highlights】**
- **TETON 2 Trial**: Expected September readout; positive results could accelerate regulatory strategy for IPF indication.
- **Nintedanib DPI**: Phase II trial (INFLO) to enroll 228 patients ex-U.S., focusing on safety and FVC efficacy signals.
- **Blackstone Financing**: $75M drawn initially; no milestones required for additional draws, supporting pediatric launch prep.
- **Afrezza Growth**: 22% YoY new prescriptions; expanding sales force to 50% market coverage by 2026.
- **Clofazimine Strategy**: Targeting U.S. and Japan NTM markets; interim trial analysis in 2026 could support fast-track approval.
- **Pediatric Launch**: Co-promotion with BAQSIMI in pediatric centers; label update submission expected Q4 2025.

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 18% to $74M, driven by Tyvaso DPI (royalties +12%, manufacturing +18%).
- **Afrezza Momentum**: NRx/TRx growth 20%/14%, top prescribers up 26% YoY; pediatric expansion could add $150M+ annually.
- **Pipeline Progress**: MNKD-101 trial 85% sites activated, 55 patients randomized; MNKD-201 Phase 1 safety data positive.
- **Financial Strength**: $198M cash, non-GAAP net income up 43% to $22M, supporting pipeline and commercial expansion.

**【CEO Opening Remarks】**
- Q1 2025 revenue grew 18%, driven by Tyvaso DPI royalties ($30M) and manufacturing revenue ($29M). Afrezza net revenue increased 3% to $15M, despite one-time adjustments.
- Endocrine business showed 20% NRx and 14% TRx growth. Pediatric Afrezza expansion filing planned for mid-2025, with potential $150M+ annual impact.
- NTM pipeline (MNKD-101) interim analysis expected by year-end; 85% of trial sites activated, 55 patients randomized.
- IPF pipeline (MNKD-201) Phase 1 safety data positive; Phase 2/3 trial design under discussion with regulators.

**【CFO Financial Review】**
- Non-GAAP net income of $22M ($0.07 EPS), up 43% YoY. GAAP net income $13M ($0.04 EPS), up 24% YoY.
- Tyvaso DPI-related revenue (royalties + manufacturing) totaled $59M, up 25% YoY. Collaboration revenue remains stable.
- Cash and investments of $198M provide runway for pipeline development and commercial growth.

**【Afrezza Diabetes Update】**
- NRx growth outpaces TRx, with top 50 prescribers up 26% YoY. Payer resistance easing; pediatric launch preparation underway.
- INHALE-3 data driving physician engagement; ATTD conference booth traffic highlighted global demand.

**【Tyvaso Collaboration】**
- 4Q trailing Tyvaso DPI revenue $1.1B, with MannKind receiving 10% royalty. TETON 1/2 trials in IPF expected to inform future strategy.
- NTM market projected to exceed $1B by 2030; inhaled clofazimine aims to address unmet need for safer, more convenient therapy.

**【Pipeline Catalysts】**
- MNKD-101 interim enrollment target (100 patients) expected by year-end; Phase 2 data in 2026.
- MNKD-201 global Phase 2/3 trial design under review; potential combination with new IPF therapies being explored.
- Payer board feedback positive on pediatric Afrezza coverage potential.

MannKind (MNKD)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: 43% YoY growth to $286 million, driven by TYVASO DPI ($102 million) and Afrezza ($64 million). Cash of $203 million supports pipeline.
- **Pediatric Breakthrough**: Afrezza pediatric filing H1 2025, targeting $200+ million annual sales. 28% of patients in trials preferred Afrezza over MDIs/AIDs.
- **Pipeline Progress**: Clofazimine Phase III 70% sites activated; nintedanib DPI Phase II planned post-FDA meeting. Expanded access program for clofazimine approved.
- **Financial Strength**: Debt reduced by $236 million; non-GAAP net income up 10x to $68 million. Steady-state margins expected from manufacturing scale.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q4 2024 revenue of $77 million, up 31% YoY; full-year revenue of $286 million, up 43% YoY. TYVASO DPI royalties contributed $102 million annually, a 42% increase.
- **Endocrine Business Unit Strength**: Q4 EBU revenue of $23 million, full-year $82 million. India launch expected H2 2025, and pediatric Afrezza filing anticipated H1 2025 with potential approval in Q2 2026.
- **Pipeline Momentum**: Clofazimine inhalation suspension Phase III study 70% sites activated, targeting 100 patient enrollment by end-2025. Nintedanib DPI Phase I completed, FDA meeting scheduled Q2 2025.
- **Financial Health**: Year-end cash of $203 million; debt reduced by $236 million, ending at $36 million. Afrezza net revenue up 17% YoY to $64 million.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: TYVASO DPI royalties $102 million (42% YoY), collaboration/services revenue $101 million (90% YoY), Afrezza $64 million (17% YoY). V-Go sales declined 4% YoY to $18 million.
- **Profitability**: Full-year net income $28 million ($0.10 EPS), up from $12 million loss in 2023. Non-GAAP net income $68 million ($0.25 EPS), up from $6 million in 2023.
- **Balance Sheet**: Debt reduced to $36 million; cash position supports pipeline and growth initiatives.

**【Q&A Highlights】**
- **Margins and Investments**: CFO expects steady-state margins due to manufacturing efficiency. CEO prioritizes pediatric Afrezza launch, with 3 key success factors: reimbursement, institutional selling, and education.
- **TYVASO DPI**: United Therapeutics (UT) expects stable gross-to-net trends. MannKind awaits UT's bridging study plans for IPF, with potential Phase II for nintedanib starting H2 2025.
- **Clofazimine**: Phase III interim analysis by mid-2026; FDA allows expanded access program to accelerate enrollment.
- **India Launch**: Cipla manufacturing approval expected Q3 2025, first shipments by end-2025.


Actual											-0.04	-0.05	-0.05	-0.11	-0.05	-0.14	-0.02	-0.11	-0.1	-0.11	-0.06	-0.07	-0.04	-0.02	0.01	0	0.04	-0.01	0.04	0.03	0.04	0	0.03	-0.05
Forecast											-0.058	-0.052	-0.046	-0.0392	-0.046	-0.0458	-0.0667	-0.067	-0.098	-0.094	-0.086	-0.0513	-0.0503	-0.038	-0.0166	0.0033	0.026	0.008	0.03	0.0357	0.0416	0.05	0.0188	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+31.03%	+3.85%	-8.70%	-180.61%	-8.70%	-205.68%	+70.01%	-64.18%	-2.04%	-17.02%	+30.23%	-36.45%	+20.48%	+47.37%	+160.24%	-100.00%	+53.85%	-225.00%	+33.33%	-15.97%	-3.85%	-100.00%	+59.57%	0.00%

MNKD

MNKD fundamentals

MNKD Q4 2025 Earnings

Earnings Call

You can ask Aime

MNKD

MNKD fundamentals

MNKD Q4 2025 Earnings

Earnings Call

MNKD Earnings Call Summary for Q4/20259:00 AM on Feb 26, 2026

MNKD Earnings Call Summary for Q3/20259:00 AM on Nov 5, 2025

MNKD Earnings Call Summary for Q2/20259:00 AM on Aug 6, 2025

MNKD Earnings Call Summary for Q1/20259:00 AM on May 8, 2025

MNKD Earnings Call Summary for Q4/20244:30 PM on Feb 26, 2025

You can ask Aime